Fig. 1
From: Whole exome sequencing-based homologous recombination deficiency test for epithelial ovarian cancer
The flowchart of the study. In training group, the gene mutation and HRD status of 40 EOC patients was examined by our WES-based scarHRD test and Myriad MyChoice® CDx test. The correlation of clinical outcomes and HRD status were analyzed. In validation group, the gene mutation and HRD status of 23 EOC patients was defined by our WES-based scarHRD test. The correlation of clinical outcomes, especially the PARPi response, and HRD status were analyzed